- Home
- KBDC vs MESO Comparison
KBDC vs MESO Comparison
Compare KBDC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBDC
- MESO
- Stock Information
- Founded
- KBDC 2021
- MESO 2004
- Country
- KBDC United States
- MESO Australia
- Employees
- KBDC N/A
- MESO N/A
- Industry
- KBDC
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KBDC
- MESO Health Care
- Exchange
- KBDC Nasdaq
- MESO Nasdaq
- Market Cap
- KBDC 1.2B
- MESO 1.2B
- IPO Year
- KBDC N/A
- MESO N/A
- Fundamental
- Price
- KBDC $16.73
- MESO $13.17
- Analyst Decision
- KBDC Buy
- MESO Strong Buy
- Analyst Count
- KBDC 5
- MESO 4
- Target Price
- KBDC $17.30
- MESO $11.50
- AVG Volume (30 Days)
- KBDC 91.0K
- MESO 238.9K
- Earning Date
- KBDC 11-13-2024
- MESO 08-28-2024
- Dividend Yield
- KBDC 3.00%
- MESO N/A
- EPS Growth
- KBDC N/A
- MESO N/A
- EPS
- KBDC N/A
- MESO N/A
- Revenue
- KBDC N/A
- MESO $5,902,000.00
- Revenue This Year
- KBDC $172.54
- MESO $66.05
- Revenue Next Year
- KBDC $14.28
- MESO $348.27
- P/E Ratio
- KBDC N/A
- MESO N/A
- Revenue Growth
- KBDC N/A
- MESO N/A
- 52 Week Low
- KBDC $15.69
- MESO $1.61
- 52 Week High
- KBDC $17.22
- MESO $12.70
- Technical
- Relative Strength Index (RSI)
- KBDC N/A
- MESO 67.62
- Support Level
- KBDC N/A
- MESO $10.30
- Resistance Level
- KBDC N/A
- MESO $11.59
- Average True Range (ATR)
- KBDC 0.00
- MESO 0.50
- MACD
- KBDC 0.00
- MESO 0.10
- Stochastic Oscillator
- KBDC 0.00
- MESO 77.98
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.